5780-66-5Relevant articles and documents
2,3,5,6-Tetra(pyrazin-2-yl)pyrazine: a novel bis-bidentate, bis-tridentate chelator
Ligiero, Carolina B.P.,Visentin, Lorenzo C.,Giacomini, Rosana,Filgueiras, Carlos A.L.,Miranda, Paulo C.M.L.
, p. 4030 - 4032 (2009)
Novel 10-nitrogen ligand, 2,3,5,6-tetra(pyrazin-2-yl)pyrazine, has been synthesized in four steps. This compound shows different conformations and the crystal structure of one of them has been established. This structure is sustained by non-classical H-bonds and π···π interactions among heteroaromatic rings.
An Engineered Alcohol Oxidase for the Oxidation of Primary Alcohols
Heath, Rachel S.,Birmingham, William R.,Thompson, Matthew P.,Taglieber, Andreas,Daviet, Laurent,Turner, Nicholas J.
, p. 276 - 281 (2019/01/04)
Structure-guided directed evolution of choline oxidase has been carried out by using the oxidation of hexan-1-ol to hexanal as the target reaction. A six-amino-acid variant was identified with a 20-fold increased kcat compared to that of the wild-type enzyme. This variant enabled the oxidation of 10 mm hexanol to hexanal in less than 24 h with 100 % conversion. Furthermore, this variant showed a marked increase in thermostability with a corresponding increase in Tm of 20 °C. Improved solvent tolerance was demonstrated with organic solvents including ethyl acetate, heptane and cyclohexane, thereby enabling improved conversions to the aldehyde by up to 30 % above conversion for the solvent-free system. Despite the evolution of choline oxidase towards hexan-1-ol, this new variant also showed increased specific activities (by up to 100-fold) for around 50 primary aliphatic, unsaturated, branched, cyclic, benzylic and halogenated alcohols.
AMINONITRILES AS KYNURENINE PATHWAY INHIBITORS
-
Page/Page column 89; 90, (2014/09/29)
The present application provides novel kynurenine pathway inhibitors and pharmaceutically acceptable salts and prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in regulating the kynurenine pathway and the activity of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase by administering a therapeutically effective amount of one or more of the compounds of formula (I) to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the kynurenine pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by immunosuppression, abnormal cellular proliferation and/or inflammation. In one embodiment, the disease is cancer. In another embodiment, the disease is a viral infection. In a further embodiment, the disease is depression.